> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# NCI Sees Revumenib Promise for Some Leukemias
- URL: https://www.fdaweb.com/nci-sees-revumenib-promise-for-some-leukemias/
- Published: 2023-04-19T12:00:00.000Z
- Updated: 2026-09-14T18:26:31.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5154252

The National Cancer Institute (NCI) says Syndax Pharmaceuticals’ revumenib, a menin inhibitor, showed promise in an early-stage clinical trial for treating acute myeloid leukemia. An NCI [statement](https://www.cancer.gov/news-events/cancer-currents-blog/2023/revumenib-menin-inhibitor-advanced-aml?cid=eb%5Fgovdel&ref=fdaweb.com) says treatment with revumenib in the AUGMENT-101 trial caused about one-third of study participants’ cancers to completely disappear. The statement says all the participants had previously received many other treatments, including in some cases a stem cell transplant.

The trial didn’t directly compare revumenib with any other drugs, the statement says. The drug is now being tested in a Phase 2 study to obtain FDA approval to treat people with advanced acute myeloid leukemia with specific gene alterations. There also are studies using revumenib in combination therapies.